Charles River Laboratories vs Minaris Advanced Therapies: CDMO Comparison

How does Charles River Laboratories compare to Minaris Advanced Therapies?

As of Aug 2026, Charles River Laboratories: 9 FDA inspections (including 6 NAI, 3 VAI and 0 OAI), 11 EMA/MHRA GMP certificates. Signal Score 86.3. Minaris Advanced Therapies: 3 FDA inspections (including 2 NAI, 1 VAI and 0 OAI), 2 EMA/MHRA GMP certificates. Signal Score 83.1. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of Charles River Laboratories and Minaris Advanced Therapies on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score
86/100
Quality (FDA + GMP)
99/100
FDA inspections
9
— NAI / VAI / OAI
6 / 3 / 0
FDA warning letters
0
EMA GMP certificates (active)
9
MHRA GMP certificates (compliant)
2
Clinical programs (matched)
0
Capacity
Limited
Modalities
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score
83/100
Quality (FDA + GMP)
99/100
FDA inspections
3
— NAI / VAI / OAI
2 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
2
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
Limited
Modalities
CAR-T, Cell Therapy

Key differences

  • Charles River Laboratories has more FDA inspections on record (9 vs 3) — a deeper regulatory paper trail.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Charles River Laboratories has materially broader EMA GMP coverage (9 active certificates vs 2) — stronger EU footprint.
  • Charles River Laboratories maintains 2 MHRA / UK GMP certificates; Minaris Advanced Therapies does not.

Across the cross-modality scorecard, Charles River Laboratories carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: Charles River Laboratories vs Minaris Advanced Therapies

How does Charles River Laboratories compare to Minaris Advanced Therapies?

On CDMO Signal's composite Signal Score, Charles River Laboratories is 86/100 and Minaris Advanced Therapies is 83/100; Charles River Laboratories has 9 FDA inspections on record vs 3 for Minaris Advanced Therapies; European coverage is 11 active EMA+MHRA certificates for Charles River Laboratories vs 2 for Minaris Advanced Therapies. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, Charles River Laboratories or Minaris Advanced Therapies?

Both Charles River Laboratories and Minaris Advanced Therapies maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Charles River Laboratories has 9 FDA inspections on record; Minaris Advanced Therapies has 3.

How do Charles River Laboratories and Minaris Advanced Therapies compare on European GMP coverage?

Charles River Laboratories holds 9 active EMA GMP certificates and 2 MHRA / UK certificates. Minaris Advanced Therapies holds 2 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

What does the Signal Score gap mean in practice?

Charles River Laboratories carries a Signal Score of 86/100 and Minaris Advanced Therapies carries 83/100 — essentially tied for Charles River Laboratories. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Charles River Laboratories and Minaris Advanced Therapies for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.